Search results
Showing 121 to 135 of 267 results for carcinoma
Awaiting development Reference number: GID-TA11813 Expected publication date: TBC
Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.
View recommendations for HTG121Show all sections
Sections for HTG121
Photodynamic therapy for early-stage oesophageal cancer (HTG128)
Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.
View recommendations for HTG128Show all sections
Sections for HTG128
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Evidence-based recommendations on stent placement for vena caval obstruction. This involves using a catheter to position a stent, which may be self-expanding or balloon-dilated, across the area of narrowing to relieve it.
View recommendations for HTG50Show all sections
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
Capecitabine for the treatment of advanced gastric cancer (TA191)
Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
Evidence-based recommendations on photodynamic therapy for brain tumours. This involves giving the patient a drug that makes the tissue sensitive to light and then activating it with a laser light source to destroy the tumour cells.
View recommendations for HTG184Show all sections
Sections for HTG184
Irreversible electroporation for primary liver cancer (HTG532)
Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.
View recommendations for HTG532Show all sections
Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.
Show all sections
Awaiting development Reference number: GID-TA11584 Expected publication date: 08 December 2027
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.
Discontinued Reference number: GID-TA10166
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC